The objective of the guideline is to help healthcare professionals make the best decisions when treating chest keloids. The guideline provides information on the causes, symptoms, diagnosis, and treatment of chest keloids.
This document provides evidence-based recommendations for managing chest keloids, categorized into six clinical groups. It emphasizes non-surgical treatments like intra-lesional triamcinolone and cryotherapy, while advising against surgery, radiation, and lasers due to risks of worsening keloids. The guidelines are based on clinical data and case studies from international dermatology experts.
The document also outlines the natural history and epidemiology of chest keloids, noting their high prevalence compared to other body regions and their tendency to be multifocal and progressive. It includes demographic data and clinical presentation variations by ethnicity, particularly highlighting the association of tumoral keloids with African American patients.
Intra-lesional triamcinolone (ILT) shall be the first-line treatment for all early-stage, papular, and linear lesions.
Surgery shall not be used in the treatment of anterior chest keloids because the disease is multifocal and progressive, and surgical intervention is a known cause for the worsening of keloids.
Contact-cryotherapy with or without ILT/ILC is the preferred and primary method of destruction of all nodular, locally advanced, and tumoral keloid lesions.